ATP binding cassette subfamily A member 17, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ABCA17P profile across patient tissues and cancer cell-line models. ABCA17P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ABCA17P is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ABCA17P RNA expression shows 15,326 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where ABCA17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCA17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCA17P survival associations across molecular data types. ABCA17P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCA17P RNA expression–survival associations across cancer types. High ABCA17P expression shows unfavorable associations in KIRP, UCEC and KICH, but favorable associations in UVM, LUAD and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ABCA17P RNA expression.
This table summarizes ABCA17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ABCA17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCA17P shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP, BRCA, LIHC and HNSC. The KIRC box plot shows higher ABCA17P RNA expression in tumor versus normal tissue (log2 FC = +0.728, t-test p < 0.001).
This table shows molecular features associated with ABCA17P in patient tissues and cancer cell lines. In patient samples, ABCA17P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
